One of the most important sources of this coverage comes from Digital Opinion Leaders (DOLs ... and internal stakeholders. MSD and Daiichi Sankyo's patritumab deruxtecan hit its main objective ...

Throw into this mix the possibility that new therapeutics may not even be based on a molecule any more – they could be a prescription digital ... MSD and Daiichi Sankyo's patritumab deruxtecan ...

Daiichi Sankyo and Merck said on Tuesday that their drug, patritumab deruxtecan, met the main goal of extending the time some ...

As Enhertu’s reach continues to spread into additional forms of breast cancer, Daiichi Sankyo and AstraZeneca are ramping up awareness of the drug among its expanded patient pool. To that end ...

The drug helped patients live significantly longer without their cancer progressing, compared with patients who were treated ...

In interviews with Fierce Pharma Marketing at Fierce’s annual Digital Pharma East event in Philadelphia last week, marketing leaders from Bayer, Daiichi Sankyo and argenx discussed that slower ...

Merck & Co. and Daiichi Sankyo on Tuesday said one of the drug candidates in their multibillion-dollar collaboration has hit its main goal in a late-stage lung-cancer study. Merck and Daiichi ...

Despite meeting the primary endpoint in a Phase III study, two patients treated with Merck and Daiichi Sankyo’s experimental ...

On Tuesday, Daiichi Sankyo Company, Limited (4568:JP) (OTC: DSNKY) shares maintained a positive outlook as TD Cowen sustained its Buy rating and JPY46.00 price target on the company's stock.

Daiichi Sankyo's ADCs, particularly trastuzumab deruxtecan (Enhertu) and datopotamab deruxtecan, are showing promising results in treating various cancers, including HER2-mutated NSCLC and HER2 ...

Daiichi Sankyo has reported positive initial findings from the dose escalation phase of the first-in-human Phase I trial of its investigational antibody-drug conjugate (ADC) DS-9606 for treating ...